Immunotherapy fails to improve PFS and OS in relapsed mesothelioma
Treatment for relapsed malignant pleural mesothelioma (MPM) received a blow yesterday when eagerly awaited survival results of a phase III trial comparing pembrolizumab with chemotherapy failed to live up to their promise. The PROMISE-meso trial…
Read More